Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179647 · ClinicalTrials.gov registry record · Phase 3
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
A Phase 3 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,913
- Enrollment target
NCT00179647: Completed Phase 3 study, sponsored by Celgene Corporation.
NCT00179647 is a Phase 3 study that has completed, run by Celgene Corporation. The registered enrollment target is 1,913 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (148% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179647, a Phase 3 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,913 participants
- Enrollment target
Study Summary
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Primary Outcome
Data from all subjects who received any study drug were included in the analysis. Adverse events were classified using the Medical Dictionary for Regulatory Activities (MedDRA) classification system. A subject having the same event more than once was counted only once. Adverse events were summarized by worst NCI (National Cancer Institute) CTCAE (Common Terminology Criteria for Adverse Events) VERSION 3.0 grade. Incidence was defined as the number of subjects who experienced an adverse event wit
Interventions
- DRUG dexamethasone
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,913 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00179647 record still lists
NCT00179647 is an interventional study that assigns participants to a tested intervention. Its 1,913 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (148% higher).
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00179647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00179647 about?
NCT00179647 is a clinical study titled "Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma". Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
What is the current status of trial NCT00179647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,913 participants. The study started on 2005-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00179647?
The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00179647?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00179647's enrollment target sits among peer trials
1,913 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia